Orphan designation: Adeno-associated virus serotype rh10 containing the human GALC gene Treatment of Krabbe disease, 15/10/2021 Positive
Overview
- Overview
This medicine was designated as an orphan medicine for the treatment of Krabbe disease in the European Union on 15 October 2021. - All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
- The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
- For more information, see:
Key facts
- Active substance
- Adeno-associated virus serotype rh10 containing the human GALC gene
- Intended use
- Treatment of Krabbe disease
- Orphan designation status
- Positive
- EU designation number
- EU/3/21/2511
- Date of designation
- Sponsor
Forge Biologics Europe S.L.